BACKGROUND/AIMS: To examine the morbidity and mortality of patients with severe fibrosis secondary to HCV infection, within a population unbiased by tertiary referral. METHODS: One hundred and fifty HCV infected patients were identified from the Trent HCV study with a liver biopsy taken before 2002 demonstrating severe fibrosis (Ishak stage > or =4). Follow-up data were extracted from the database and hospital records. RESULTS: Median follow-up was 51 months. Of the 131 patients with no prior history of decompensation, 33 (25%) died (n=25) or were transplanted (n=8), after a median interval of 42 months. The probability of survival without liver transplantation was 97%, 88%, and 78% at 1, 3, and 5 years, respectively. Hepatocellular carcinoma and/or decompensation was diagnosed in 33 (25%), after a median interval of 41 months. In multivariate analysis, combination antiviral therapy was associated with improved survival. Prognosis was not affected by the Ishak stage at index biopsy. There was a worse prognosis for the 19 patients with previous decompensation; 17 (89%) having either died (n=15) or been transplanted (n=2). CONCLUSIONS: This study demonstrates that severe liver fibrosis (Ishak stage > or = 4) secondary to hepatitis C is associated with a poor prognosis, that may be improved following combination antiviral treatment.
BACKGROUND/AIMS: To examine the morbidity and mortality of patients with severe fibrosis secondary to HCV infection, within a population unbiased by tertiary referral. METHODS: One hundred and fifty HCV infectedpatients were identified from the Trent HCV study with a liver biopsy taken before 2002 demonstrating severe fibrosis (Ishak stage > or =4). Follow-up data were extracted from the database and hospital records. RESULTS: Median follow-up was 51 months. Of the 131 patients with no prior history of decompensation, 33 (25%) died (n=25) or were transplanted (n=8), after a median interval of 42 months. The probability of survival without liver transplantation was 97%, 88%, and 78% at 1, 3, and 5 years, respectively. Hepatocellular carcinoma and/or decompensation was diagnosed in 33 (25%), after a median interval of 41 months. In multivariate analysis, combination antiviral therapy was associated with improved survival. Prognosis was not affected by the Ishak stage at index biopsy. There was a worse prognosis for the 19 patients with previous decompensation; 17 (89%) having either died (n=15) or been transplanted (n=2). CONCLUSIONS: This study demonstrates that severe liver fibrosis (Ishak stage > or = 4) secondary to hepatitis C is associated with a poor prognosis, that may be improved following combination antiviral treatment.
Authors: G Shiha; S Seif; A Eldesoky; M Elbasiony; R Soliman; A Metwally; K Zalata; N Mikhail Journal: Hepatol Int Date: 2017-04-19 Impact factor: 6.047
Authors: John C Hoefs; Mitchell L Shiffman; Zachary D Goodman; David E Kleiner; Jules L Dienstag; Anne M Stoddard Journal: Gastroenterology Date: 2011-06-12 Impact factor: 22.682
Authors: Jules L Dienstag; Marc G Ghany; Timothy R Morgan; Adrian M Di Bisceglie; Herbert L Bonkovsky; Hae-Young Kim; Leonard B Seeff; Gyongyi Szabo; Elizabeth C Wright; Richard K Sterling; Gregory T Everson; Karen L Lindsay; William M Lee; Anna S Lok; Chihiro Morishima; Anne M Stoddard; James E Everhart Journal: Hepatology Date: 2011-06-23 Impact factor: 17.425
Authors: Dalia Omran; Ayman Yosry; Samar K Darweesh; Mohammed M Nabeel; Mohammed El-Beshlawey; Sameh Saif; Azza Fared; Mohamed Hassany; Rania A Zayed Journal: Clin Exp Med Date: 2017-05-31 Impact factor: 3.984
Authors: Anna S Lok; Leonard B Seeff; Timothy R Morgan; Adrian M di Bisceglie; Richard K Sterling; Teresa M Curto; Gregory T Everson; Karen L Lindsay; William M Lee; Herbert L Bonkovsky; Jules L Dienstag; Marc G Ghany; Chihiro Morishima; Zachary D Goodman Journal: Gastroenterology Date: 2008-09-18 Impact factor: 22.682
Authors: James E Everhart; Elizabeth C Wright; Zachary D Goodman; Jules L Dienstag; John C Hoefs; David E Kleiner; Marc G Ghany; A Scott Mills; S Russell Nash; Sugantha Govindarajan; Thomas E Rogers; Joel K Greenson; Elizabeth M Brunt; Herbert L Bonkovsky; Chihiro Morishima; Heather J Litman Journal: Hepatology Date: 2010-02 Impact factor: 17.425